Prediction of suboptimal cytoreduction of epithelial ovarian carcinoma by preoperative computed tomography

European Journal of Gynaecological Oncology

Volumn 31, Issue 1, 2010, Pages 44-49

  Kebapci, M ^a   Akca, A K ^a   Yalcin, O T ^a   Ozalp, S S ^a   Calisir, C ^a   Mutlu, F ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Computed tomography; Cytoreduction; Ovarian carcinoma

Indexed keywords

ADRENAL GLAND; ADULT; AGED; ARTICLE; CANCER CELL; CANCER INFILTRATION; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; CELL SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMPLANT; LIGAMENT; LIVER; LYMPH NODE; MESENTERY; OMENTUM; OUTCOME ASSESSMENT; OVARY CARCINOMA; PELVIS; PERITONEUM; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPLEEN; STOMACH; TREATMENT OUTCOME; TUMOR VOLUME;

ABDOMINAL NEOPLASMS; ADULT; AGED; CARCINOMA; CONTRAST MEDIA; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIOGRAPHY, ABDOMINAL; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77349104106     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Landis S.H., Murray T., Bolden S., Wingo P.A.: "Cancer statistics, 1998". CA Cancer J. Clin., 1998, 48, 6.
2. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: "Cancer statistics 2004". CA Cancer J. Clin., 2004, 54, 8.
3. Pecorrelli S., Benedet J.L., Creasman W.T., Shaperd J.H.: "FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics". Int. J. Gynaecol. Obstet., 1999, 64, 5.
4. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study". Gynecol. Oncol., 1992, 47, 159.
5. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M. et al.: "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.
6. Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J. et al.: "Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience". J. Clin. Oncol., 1991, 9, 1138.
7. Dowdy S.C., Mullany S.A., Brandt K.R., Huppert B.J., Cliby W.A.: "The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma". Cancer, 2004, 101, 346.
8. Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O'Neill M.J., Trimble E.L. et al.: "A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography". Cancer, 2000, 89, 1532.
9. Seifer D.B., Kennedy A.W., Webster K.D., Vanderbrug Medendorp S., Isakson D.G.: "Outcome of primary cytoreductive surgary advanced epithelial ovarian carcinoma". Cleve Clin. J. Med., 1988, 55, 555.
10. Hoskins W.J.: "Epithelial ovarian carcinoma: principles of primary surgery". Gynecol. Oncol., 1994, 55, 91.
11. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., Van Dam P.: "Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients". Gynecol. Oncol., 1998, 71, 431.
12. Eisenkop S.M., Friedman R.L., Wang H.J.: "Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study". Gynecol. Oncol., 1998, 69, 103.
13. Hoskins W.J.: "The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer". Baillieres Clin Obstet Gynaecol., 1989, 3, 59.
14. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.L., Thiel R.P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival". Gynecol. Oncol., 1999, 72, 93.
15. Vergote I.B., De Wever I., Decloedt J., Tjalma W., Van Gramberen M., van Dam P.: "Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer". Semin. Oncol., 2000, 27, 31.
16. Meyer J.I., Kennedy A.W., Friedman R., Ayoub A., Zepp R.C.: "Ovarian carcinoma: value of CT in predicting success of debulking surgery". AJR Am. J. Roentgenol., 1995, 165, 875.
17. Nelson B.E., Rosenfield A.T., Schwartz P.E.: "Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma". J. Clin. Oncol., 1993, 11, 166.
18. Qayyum A., Coakley F.V., Westphalen A.C., Hricak H., Okuno W.T., Powell B.: "Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer". Gynecol. Oncol., 2005, 96, 301.
19. Byrom J., Widjaja E., Redman C.W.E., Jones P.W., Tebby S.: "Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?". BJOG, 2002, 109, 369.
20. Schwartz P.E., Chambers J.T., Makuch R.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Gynecol. Oncol., 1994, 53, 33.
21. Fanfani F., Ferrandina G., Corrado G., Fagotti A., Zakut H.V., Mancuso S. et al.: "Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO Stage IIIC ovarian cancer patients". Oncology, 2003, 65, 316.
22. Morice P., Dubemard G., Rey A., Atallah D., Pautier P., Pomel C. et al.: "Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer". J. Am. Coll. Surg., 2003, 197, 955.
23. Aletti G.D., Gostout B.S., Podratz K.C., Cliby W.A.: "Ovarian cancer resectability: relative impact of disease, patient status, and surgeon". Gynecol. Oncol., 2006, 100, 33.
24. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S. et al.: "Multi-institutional reciprocal validation study of computed tomography predictors suboptimal primary cytoreduction in patients with advanced ovarian cancer". J. Clin. Oncol., 2007, 25, 384.